Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Medchemexpress LLC Rebastinib | 1020172-07-9 | 99.8% | 100 MG
Supplier: Medchemexpress LLC HY13024100MG
Rebastinib (DCC-2036) is an orally active, non-ATP-competitive inhibitor targeting Bcr-Abl, including resistant mutants. It effectively inhibits Abl1WT and Abl1T315I, as well as SRC, KDR, FLT3, and Tie-2, with low activity against c-Kit. This compound demonstrates potent antiproliferative effects in various leukemia cell lines and significantly prolongs survival in animal models of leukemia.
- Potently inhibits ABL1 native and ABL1 T315I.
- Inhibits SRC family kinases and PDGFRα/β.
- Selectively spares c-KIT.
- Effectively inhibits proliferation of native BCR-ABL1 and Ph+ K562 cell lines.
- Inhibits proliferation of common TKI-resistant BCR-ABL1 mutants.
- Reduces leukemia cell burden in treated mice.
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?